News

The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by

These single-use culture containers are designed by Saint-Gobain to provide a closed systems approach to cell culture and cell manufacturing, allowing for a seamless translation of bioprocesses from

The approval is said to confirm the Cosentyx efficacy in the treatment of axial spondyloarthritis (axSpA) disease spectrus. Cosentyx is claimed to be the first and only fully-human

In Neuville sur Saône in eastern France, Sanofi will build its Evolutive Vaccine Facility (EVF) with an investment of €490m over a five-year period. The vaccine production site

The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years.  IDEAYA has solved

Under the strategic collaboration, the companies will develop and commercialise compounds in Takeda’s early-to-mid-stage psychiatry pipeline. As part of the deal, Neurocrine has secured an exclusive licence for

The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is composed of a composite of CV death, nonfatal myocardial infarction or nonfatal

The data demonstrated daratumumab SC in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a significantly higher haematologic complete response rate (CR), 53 percent vs. 18 percent

The approval of Zepzelca is for treating metastatic small cell lung cancer in adults whose disease has progressed on or after platinum-based chemotherapy. The alkylating drug, which is